SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Soleno Therapeutics Inc (SLNO) is not a strong buy at this moment for a beginner investor with a long-term focus. While analysts have raised price targets and maintain positive ratings, the technical indicators are bearish, insiders are selling heavily, and financial performance shows significant declines in net income and EPS. The lack of recent news or Congress trading data further reduces confidence in immediate upside potential. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investment is recommended until stronger positive signals emerge.
The technical indicators for SLNO are bearish. The MACD is negative and expanding downward, RSI is neutral at 32.987, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 38.276, with resistance at 43.758. Short-term stock trend analysis suggests a 50% chance of a -0.86% move in the next day and further declines in the next week and month.
Analysts have raised price targets significantly, with Wells Fargo increasing to $114 and H.C. Wainwright to $120, citing strong sales performance and a favorable free cash flow profile. Gross margin remains high at 98.27%.
Insiders are selling heavily, with a 1314.42% increase in selling over the last month. Financial performance in Q3 2025 showed a sharp decline in net income (-133.95% YoY) and EPS (-125.68% YoY). Technical indicators are bearish, and there is no recent news or Congress trading data to support a positive outlook.
In Q3 2025, revenue remained flat YoY at $66.02M, but net income dropped significantly to $26.01M (-133.95% YoY), and EPS fell to 0.47 (-125.68% YoY). Gross margin remained strong at 98.27%, but the overall financial performance indicates declining profitability.
Analysts are optimistic, with Wells Fargo and H.C. Wainwright raising price targets to $114 and $120, respectively, and maintaining Overweight/Buy ratings. Wolfe Research initiated coverage with an Outperform rating and a $75 price target, noting that safety concerns are overblown and utilization trends are favorable for the next 1-2 years.
